Tidepath

Amylin drugs

Cagrilintide

A long-acting version of amylin, tested as a once-a-week injection12.

Status
Not approved by the FDA, and in phase 3 trials on its own as of October 2026856.
How it's taken
By injection

What it is

Cagrilintide is a lab-made, long-acting version of amylin12. Natural amylin is a hormone from the pancreas that brings on a feeling of fullness1. It's released together with insulin after you eat7. In animal and lab studies, amylin also slowed how fast the stomach empties and lowered glucagon, a hormone that raises blood sugar7. Cagrilintide carries an attached fatty chain (it's lipidated) and is built to be long-acting2. In an early trial where it was given once a week together with semaglutide, its half-life, the time it takes for half a dose to clear, was 159 to 195 hours, about a week3.

What makes it distinct

Cagrilintide is one half of CagriSema, and it's also being tested on its own: the RENEW phase 3 trials, which compare cagrilintide alone with placebo, began in November 2025456.

What the evidence shows

A phase 2 trial ran for 26 weeks in adults without diabetes who had obesity, or overweight plus high blood pressure or unhealthy blood fat levels1. People on cagrilintide lost more weight than people on placebo (a dummy injection) at every dose tested1. The most frequent side effects were stomach and gut problems, such as nausea, constipation and diarrhoea, and reactions where the injection was given1. REDEFINE 1, a phase 3 trial of CagriSema, also included a group of 302 people who took cagrilintide on its own4. Phase 3 trials of cagrilintide alone, called RENEW, are testing it against placebo in adults with overweight or obesity, with and without type 2 diabetes56.

Open questions

  • Results of the RENEW phase 3 trials. RENEW 1 expects to finish collecting data for its main result in May 20275.
  • How it does on its own in phase 3. The published summary of REDEFINE 1 reports the combination against placebo, not the cagrilintide-only group, so those results aren't covered here4.
  • Effects over longer periods. The longest trials of cagrilintide alone in our sources run 64 to 68 weeks45.

Sources

  1. Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 2021;398:2160-2172. PMID 34798060
  2. Kruse T et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem 2021;64(15):11183-11194. PMID 34288673
  3. Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide for weight management: a randomised, controlled, phase 1b trial. Lancet 2021 (PubMed 33894838)
  4. Garvey WT et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med 2025;393:635-647. PMID 40544433
  5. ClinicalTrials.gov NCT07220642: RENEW 1, Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity
  6. ClinicalTrials.gov NCT07220759: RENEW 2, Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 Diabetes
  7. SYMLIN (pramlintide acetate) injection, FDA prescribing information (DailyMed, revised 12/2019)
  8. FDA: Novel Drug Approvals for 2026 (content current as of 10/20/2026)

More in Amylin drugs